Document is current
Any future updates will be listed below
-
Authors
Platten, Michael
Kisten, Yogan
Kälvesten, Johan
Arnaud, Laurent
Forslind, Kristina
Vollenhoven, Ronald van
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00764725 at ClinicalTrials.govnct00764725 at ClinicalTrials.govDocuments that mention this clinical trial
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
https://doi.org/10.1016/s0140-6736(12)60027-0
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
https://doi.org/10.1136/annrheumdis-2013-204986
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
https://doi.org/10.1136/annrheumdis-2013-205060
Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
https://doi.org/10.1136/rmdopen-2017-000458
Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
https://doi.org/10.1136/rmdopen-2016-000369
Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
https://doi.org/10.1136/ard.2010.139212
Documents that mention this clinical trial
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
https://doi.org/10.1016/s0140-6736(12)60027-0
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
https://doi.org/10.1136/annrheumdis-2013-204986
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
https://doi.org/10.1136/annrheumdis-2013-205060
Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
https://doi.org/10.1136/rmdopen-2017-000458
Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
https://doi.org/10.1136/rmdopen-2016-000369
Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial
https://doi.org/10.1136/ard.2010.139212
-
Funding
Funding for this research was provided by:
Stockholm County
Schering-Plough/Merck Sharp and Dohme
Swedish Rheumatism Foundation
The foundation for assistance to disabled people in Skne
